Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Voyager Therapeut (VYGR)

11.03   0.01 (0.09%) 10-24 12:58
Open: 11.1 Pre. Close: 11.02
High: 11.48 Low: 10.925
Volume: 169,648 Market Cap: 413M
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The firm focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The firm's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The firm's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.495 - 11.541 11.541 - 11.586
Low: 10.817 - 10.868 10.868 - 10.915
Close: 10.95 - 11.028 11.028 - 11.103

Technical analysis

as of: 2020-10-23 4:50:22 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 13.76     One year: 14.78
Support: Support1: 10.38    Support2: 8.64
Resistance: Resistance1: 11.78    Resistance2: 12.65
Pivot: 11.60
Moving Average: MA(5): 11.20     MA(20): 11.41
MA(100): 11.92     MA(250): 12.05
MACD: MACD(12,26):     Signal(9): 0.09
Stochastic oscillator: %K(14,3): 25.16     %D(3): 33.64
RSI: RSI(14): 44.24
52-week: High: 16.53  Low: 6.26  Change(%): -27.7
Average Vol(K): 3-Month: 22570  10-Days: 17741

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
VYGR has closed above bottom band by 19.6%. Bollinger Bands are 10.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 14 Sep 2020
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer - GlobeNewswire

Fri, 11 Sep 2020
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease - GlobeNewswire

Thu, 03 Sep 2020
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020 - GlobeNewswire

Mon, 10 Aug 2020
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates - GlobeNewswire

Mon, 03 Aug 2020
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations - GlobeNewswire

Tue, 16 Jun 2020
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 37
Shares Float (M) 24
% Held by Insiders 15.17
% Held by Institutions 85.84
Shares Short (K) 2,160
Shares Short P. Month (K) 2,220

Stock Financials

EPS -1.640
EPS Est This Year -2.870
EPS Est Next Year -2.760
Book Value (p.s.) 2.070
Profit Margin -60.61
Operating Margin -65.08
Return on Assets (ttm) -11.8
Return on Equity (ttm) -62.0
Qtrly Rev. Growth -37.8
Gross Profit (p.s.) -0.410
Sales Per Share 2.668
EBITDA (p.s.) -1.650
Qtrly Earnings Growth
Operating Cash Flow (M) -95
Levered Free Cash Flow (M) -36

Stock Valuations

PE Ratio -6.73
PEG Ratio
Price to Book value 5.33
Price to Sales 4.13
Price to Cash Flow -4.35

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.